The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
104080333 10408033 3 F 20140708 20160810 20140825 20160816 EXP JP-JNJFOC-20140821981 JANSSEN 50.45 YR A M Y 55.00000 KG 20160816 MD JP JP

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
104080333 10408033 1 PS SOVRIAD SIMEPREVIR 1 Oral N 205123 100 MG CAPSULE QD
104080333 10408033 2 SS PEGASYS PEGINTERFERON ALFA-2A 1 Subcutaneous Y 0 180 UG INJECTION /wk
104080333 10408033 3 SS PEGASYS PEGINTERFERON ALFA-2A 1 Subcutaneous Y 0 90 UG INJECTION /wk
104080333 10408033 4 SS PEGASYS PEGINTERFERON ALFA-2A 1 Subcutaneous Y 0 90 UG INJECTION /wk
104080333 10408033 5 SS PEGASYS PEGINTERFERON ALFA-2A 1 Subcutaneous Y 0 180 UG INJECTION /wk
104080333 10408033 6 SS PEGASYS PEGINTERFERON ALFA-2A 1 Subcutaneous Y 0 90 UG INJECTION /wk
104080333 10408033 7 SS PEGASYS PEGINTERFERON ALFA-2A 1 Subcutaneous Y 0 180 UG INJECTION /wk
104080333 10408033 8 SS PEGASYS PEGINTERFERON ALFA-2A 1 Subcutaneous Y 0 90 UG INJECTION /wk
104080333 10408033 9 C RIBAVIRIN. RIBAVIRIN 1 Oral 0 600 MG QD
104080333 10408033 10 C NEXIUM ESOMEPRAZOLE MAGNESIUM 1 Oral 0 20 MG UNSPECIFIED QD
104080333 10408033 11 C NEXIUM ESOMEPRAZOLE MAGNESIUM 1 Oral 0 20 MG UNSPECIFIED QD
104080333 10408033 12 C RINDERON V BETAMETHASONE VALERATE 1 Topical AT A SMALL AMOUNT 0
104080333 10408033 13 C HIRUDOID (HEPARINOID) 2 Topical AT A SMALL AMOUNT 0 OINTMENT

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
104080333 10408033 1 Chronic hepatitis C
104080333 10408033 2 Chronic hepatitis C
104080333 10408033 3 Chronic hepatitis C
104080333 10408033 4 Chronic hepatitis C
104080333 10408033 5 Chronic hepatitis C
104080333 10408033 6 Chronic hepatitis C
104080333 10408033 7 Chronic hepatitis C
104080333 10408033 8 Chronic hepatitis C
104080333 10408033 9 Chronic hepatitis C
104080333 10408033 10 Prophylaxis
104080333 10408033 11 Prophylaxis
104080333 10408033 12 Pruritus
104080333 10408033 13 Pruritus

Outcome of event

Event ID CASEID OUTC COD
104080333 10408033 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
104080333 10408033 Neutrophil count decreased
104080333 10408033 White blood cell count decreased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
104080333 10408033 1 20140415 20140707 0
104080333 10408033 2 20140722 20140805 0
104080333 10408033 4 20140708 20140715 0
104080333 10408033 5 20140415 20140701 0
104080333 10408033 8 20140812 20140819 0
104080333 10408033 9 20140415 0
104080333 10408033 10 20140708 20140929 0
104080333 10408033 11 20140415 20140707 0
104080333 10408033 12 20140415 0
104080333 10408033 13 20140812 0